The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 05, 2016
Filed:
Sep. 09, 2014
Applicant:
Triact Therapeutics, Inc., San Francisco, CA (US);
Inventors:
Thomas F. White, San Francisco, CA (US);
Dan Hoth, San Francisco, CA (US);
Assignee:
Triact Therapeutics, Inc., San Francisco, CA (US);
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/282 (2006.01); A61K 31/403 (2006.01); A61K 45/06 (2006.01); A61K 33/24 (2006.01); A61K 31/517 (2006.01); A61K 31/5377 (2006.01); A61K 31/506 (2006.01); A61K 31/47 (2006.01); A61K 31/53 (2006.01);
U.S. Cl.
CPC ...
A61K 45/06 (2013.01); A61K 31/282 (2013.01); A61K 31/403 (2013.01); A61K 31/47 (2013.01); A61K 31/506 (2013.01); A61K 31/517 (2013.01); A61K 31/53 (2013.01); A61K 31/5377 (2013.01); A61K 33/24 (2013.01);
Abstract
The present application relates to compositions and methods for treating a proliferative disorder by administering to a subject a pharmaceutical composition of a dual kinase inhibitor. Catecholic butanes cane serve as dual kinase inhibitors for purposes of methods described herein. Patients to be treated include those that have been treated with Tarceva or other therapeutic compounds and relapsed or are resistant to treatment. The compounds described herein may exhibit a synergistic effect when administered with another agent.